Generics Bulletin Explains: The Next Wave Of US Humira Biosimilars
Start Of July Will See An Explosion Of Competition On Adalimumab In US From Eight Rivals
Following Amgen’s debut of the first US Humira rival earlier this year, as many as eight further FDA-approved adalimumab biosimilars are about to launch. Generics Bulletin breaks down all the different players and how they are positioning themselves in such a competitive market.
